Frequently asked questions
The COVID-19 pandemic’s impact on the market has been significant because it immediately stopped needless medical operations
North America accounted for the most heightened share market.
Increasing lung cancer cases and rise in cancer awareness programs to drive the checkpoint inhibitor refractory cancer market.
The CTLA-4 Inhibitor segment had a major share in the global market in 2022.
The lung cancer segment had a major share in the global market.